A phase 1b/2 study of a novel anti-ctla-4 neobodytm adg116 monotherapy and in combination with toripalimab (tori; anti-pd-1 antibody) in patients with advanced/metastatic solid tumors
JOURNAL FOR IMMUNOTHERAPY OF CANCER(2022)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要